Evolutionary determinants of cancer

Cancer Discovery

Volumn 5, Issue 8, 2015, Pages 806-821

  Greaves, Mel ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CANCER STEM CELL; CELL RENEWAL; CHROMOSOMAL INSTABILITY; CLONAL EVOLUTION; ECOSYSTEM RESILIENCE; EPIGENETICS; EVOLUTIONARY ADAPTATION; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRACELLULAR SIGNALING; LONGEVITY; NEOPLASM; NONHUMAN; PHYLOGENOMICS; PLASTICITY; REVIEW; SIGNAL TRANSDUCTION; XENOTRANSPLANTATION; METABOLISM; MOLECULAR EVOLUTION; NEOPLASMS; RISK;

CLONAL EVOLUTION; EVOLUTION, MOLECULAR; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; RISK;

EID: 84938773709     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0439     Document Type: Review

References (201)

1. Stewart BW, Wild CP, editors. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014.
2. Varmus H, Kumar HS. Addressing the growing international challenge of cancer: a multinational perspective. Sci Transl Med 2013;5:175cm2.
3. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 2015;27:15-26.
4. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med 2013;368:842-51.
5. Boveri T. The origin of malignant tumors. London: Baillière Tindall & Cox; 1929.
6. Foulds L. The natural history of cancer. J Chronic Dis 1958;8:2-37.
7. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
8. Cairns J. Mutation selection and the natural history of cancer. Nature 1975;255:197-200. Greaves
9. Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet 2012;13:795-806.
10. Sottoriva A, Kang H, Ma Z, Graham TA, Salomon MP, Zhao J, et al. A Big Bang model of human colorectal tumor growth. Nat Genet 2015;47:209-16.
11. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014;46:225-33.
12. Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, Vay C, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008;13:441-53.
13. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011;469:356-61.
14. Potter NE, Ermini L, Papaemmanuil E, Cazzaniga G, Vijayaraghavan G, Titley I, et al. Single-cell mutational profi ling and clonal phylogeny in cancer. Genome Res 2013;23:2115-25.
15. Meyer M, Reimand J, Lan X, Head R, Zhu X, Kushida M, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci U S A 2015;112:851-6.
16. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014;512:155-60.
17. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014;344:1396-401.
18. Ramskold D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol 2012;30:777-82.
19. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472:90-4.
20. Delsuc F, Brinkmann H, Philippe H. Phylogenomics and the reconstruction of the tree of life. Nat Rev Genet 2005;6:361-75.
21. McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med 2015;7:283ra54.
22. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
23. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010;467:1109-13.
24. Murtaza M, Dawson S-J, Tsui DWY, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12.
25. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in earlyand late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
26. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014;6:254ra125.
27. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014;346:251-6.
28. Ma Y, Dobbins SE, Sherborne AL, Chubb D, Galbiati M, Cazzaniga G, et al. Developmental timing of mutations revealed by wholegenome sequencing of twins with acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2013;110:7429-33.
29. Hong D, Gupta R, Ancliffe P, Atzberger A, Brown J, Soneji S, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008;319:336-9.
30. Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood 2003;102:2321-33.
31. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identifi cation of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506:328-33.
32. Gould SJ, Eldridge N. Punctuated equilibria: the tempo and mode of evolution reconsidered. Paleobiol 1977;3:115-51.
33. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell 2013;153:666-77.
34. Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet 2015;47:257-62.
35. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27-40.
36. Hart JR, Zhang Y, Liao L, Ueno L, Du L, Jonkers M, et al. The butterfly effect in cancer: a single base mutation can remodel the cell. Proc Natl Acad Sci U S A 2015;112:1131-6.
37. Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougnez C, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 2012;122:2983-8.
38. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
39. Merlo LMF, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6:924-35.
40. Pienta KJ, McGregor N, Axelrod R, Axelrod DE. Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol 2008;1:158-64.
41. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008;8:56-61.
42. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481: 306-13.
43. Breen MS, Kemena C, Vlasov PK, Notredame C, Kondrashov FA. Epistasis as the primary factor in molecular evolution. Nature 2012;490:535-8.
44. Vermeulen L, Morrissey E, van der Heijden M, Nicholson AM, Sottoriva A, Buczacki S, et al. Defi ning stem cell dynamics in models of intestinal tumor initiation. Science 2013;342:995-8.
45. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
46. Ståhl PL, Stranneheim H, Asplund A, Berglund L, Pontén F, Lundeberg J. Sun-induced nonsynonymous p53 mutations are extensively accumulated and tolerated in normal appearing human skin. J Invest Dermatol 2011;131:504-8.
47. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy related acute myeloid leukaemia. Nature 2015;518:552-5.
48. Bartesaghi S, Graziano V, Galavotti S, Henriquez NV, Betts J, Saxena J, et al. Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells. Proc Natl Acad Sci USA 2015;112:1059-64.
49. Ashur-Fabian O, Avivi A, Trakhtenbrot L, Adamsky K, Cohen M, Kajakaro G, et al. Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation. Proc Natl Acad Sci U S A 2004;101:12236-41.
50. Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009;16:458-62.
51. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 2001;293:876-80.
52. Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MTL, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. New Engl J Med 2009;361:478-88.
53. Isoda T, Ford AM, Tomizawa D, Van Delft FW, Gonzalez De Castro D, Mitsuiki N, et al. Immunologically silent cancer clone transmission from mother to offspring. Proc Natl Acad Sci U S A 2009;106:17882-5.
54. Polak P, Karlic R, Koren A, Thurman R, Sandstrom R, Lawrence MS, et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 2015;518:360-4.
55. Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 2015;372:601-12.
56. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010;24:1731-45.
57. Archetti M, Ferraro DA, Christofori G. Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer. Proc Natl Acad Sci U S A 2015;112:1833-8.
58. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-45.
59. Klein CA. Selection and adaptation during metastatic cancer progression. Nature 2013;501:365-72.
60. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999;9:M57-60.
61. Sotillo R, Schvartzman JM, Socci ND, Benezra R. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 2010;464:436-40.
62. Bjedov I, Tenaillon O, Gerard B, Souza V, Denamur E, Radman M, et al. Stress-induced mutagenesis in bacteria. Science 2003;300: 1404-9.
63. Greaves M. Does everyone develop covert cancer? Nat Rev Cancer 2014;14:209-10.
64. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371:2477-87.
65. Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 015;348:880-6.
66. Nowak MA, Sigmund K. Evolutionary dynamics of biological games. Science 2004;303:793-9.
67. Michor F, Iwasa Y, Nowak MA. Dynamics of cancer progression. Nat Rev Cancer 2004;4:197-205.
68. Anderson AR, Quaranta V. Integrative mathematical oncology. Nat Rev Cancer 2008;8:227-34.
69. Crespi B, Summers K. Evolutionary biology of cancer. Trends Ecol Evol 2005;20:545-52.
70. Kreso A, O’Brien CA, van Galen P, Gan OI, Notta F, Brown AM, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013;339:543-8.
71. Schwab ED, Pienta KJ. Cancer as a complex adaptive system. Med Hypotheses 1996;47:235-41.
72. Kitano H. Biological robustness. Nat Rev Genet 2004;5:826-37.
73. Carlson JM, Doyle J. Complexity and robustness. Proc Natl Acad Sci USA 2002;99(Suppl1):2538-45.
74. Boehm T. Design principles of adaptive immune systems. Nat Rev Immunol 2011;11:307-17.
75. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 2004;4:227-35.
76. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714-26.
77. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.
78. Monod J. Chance and necessity. New York: Alfred A. Knopf; 1970
79. D’Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, et al. Antibiotic resistance is ancient. Nature 2011;477:457-61.
80. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
81. Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007;110:727-34.
82. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46.
83. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007;5:48-56.
84. Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008;135:1118-29.
85. Turke AB, Zejnullahu K, Wu Y-L, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplifi cation in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88.
86. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9.
87. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
88. Wagner A. Arrival of the fittest. Canada: One World Publications; 2014.
89. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, et al. The genetic landscape of a cell. Science 2010;327:425-31.
90. Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral pro- gram for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 2014;346:1248012.
91. Bosch TC. Hydra and the evolution of stem cells. Bioessays 2009;31: 478-86.
92. Sanchez Alvarado A. Cellular hyperproliferation and cancer as evolutionary variables. Curr Biol 2012;22:R772-8.
93. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012;44:23-31.
94. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009;138:1083-95.
95. Wend P, Holland JD, Ziebold U, Birchmeier W. Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol 2010;21:855-63.
96. Humphries A, Cereser B, Gay LJ, Miller DS, Das B, Gutteridge A, et al. Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. Proc Natl Acad Sci U S A 2013;110:E2490-9.
97. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012;488: 527-30.
98. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell2 014;14:275-91.
99. Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr H-A, Delaloye J-F, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature2 012;481:85-9.
100. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009;138:822-9
101. Greaves M. Cancer stem cells as ‘units of selection’. Evol Appl 2013;6:102-8.
102. Rinkevich B. A critical approach to the definition of Darwinian units of selection. Biol Bull 2000;199:231-40.
103. Lewontin RC. The units of selection. Annu Rev Ecol Syst 1970;1:1-18
104. Buss LW. The evolution of individuality. Princeton, New Jersey: Princeton University Press; 1987.
105. Michod RE. Darwinian dynamics: evolutionary transitions in fitness and individuality. Princeton: Princeton University Press; 1999
106. Hughes WO, Boomsma JJ. Genetic royal cheats in leaf-cutting ant societies. Proc Natl Acad Sci U S A 2008;105:5150-3.
107. Gilbert OM, Foster KR, Mehdiabadi NJ, Strassmann JE, Queller DC. High relatedness maintains multicellular cooperation in a social amoeba by controlling cheater mutants. Proc Natl Acad Sci U S A 2007;104:8913-7.
108. Greaves M. Cancer. The evolutionary legacy. Oxford: Oxford University Press; 2000.
109. Israel L. Tumour progression: random mutations or an integrated survival response to cellular stress conserved from unicellular organisms? J Theor Biol 1996;178:375-80.
110. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012;12:487-93.
111. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 2015;518:422-6.
112. Piccirillo SGM, Colman S, Potter NE, van Delft FW, Lillis S, Carnicer M-J, et al. Genetic and functional diversity of propagating cells in glioblastoma. Stem Cell Reports 2015;4:7-15.
113. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011;146:633-44.
114. Tetteh PW, Farin HF, Clevers H. Plasticity within stem cell hierarchies in mammalian epithelia. Trends Cell Biol 2015;25:100-8
115. Visvader JE. Cells of origin in cancer. Nature 2011;469:314-22
116. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-33.
117. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465-72.
118. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
119. Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, Susky E, et al. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 2010;7:279-317.
120. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-8.
121. Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, et al. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res 2011;71:1772-80.
122. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009;324:1670-3.
123. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012;21:283-96
124. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, et al. Stem cell gene expression programs infl uence clinical outcome in human leukemia. Nat Med 2011;17:1086-93.
125. Merlos-Suárez A, Barriga FM, Jung P, Iglesias M, Virtudes Céspedes M, Rossell D, et al. The intestinal stem cell signature identifi es colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011;8:511-24.
126. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010;140:62-73
127. Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010;120:636-44.
128. van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005;11:6520-7.
129. Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A 2015;112:1839-44.
130. Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 2014;20:29-36.
131. Zhu Z, Khan MA, Weiler M, Blaes J, Jestaedt L, Geibert M, et al. Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Cell Stem Cell 2014;15: 185-98.
132. Aktipis CA, Boddy AM, Jansen G, Hibner U, Hochberg ME, Maley CC, et al. Cancer across the tree of life: cooperation and cheating in multicellularity. Phil Trans R Soc B 2015;370:20140219.
133. Domazet-Loso T, Klimovich A, Anokhin B, Anton-Erxleben F, Hamm MJ, Lange C, et al. Naturally occurring tumours in the basal metazoan Hydra. Nat Commun 2014;5:4222.
134. Hammerschmidt K, Rose CJ, Kerr B, Rainey PB. Life cycles, fitness decoupling and the evolution of multicellularity. Nature 2014;515:75-9.
135. Domazet-Loso T, Tautz D. Phylostratigraphic tracking of cancer genes suggests a link to the emergence of multicellularity in metazoa. BMC Biol 2010;8:66.
136. Lu WJ, Amatruda JF, Abrams JM. p53 ancestry: gazing through an evolutionary lens. Nat Rev Cancer 2009;9:758-62.
137. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307-15.
138. Streichan SJ, Hoerner CR, Schneidt T, Holzer D, Hufnagel L. Spatial constraints control cell proliferation in tissues. Proc Natl Acad Sci USA2014;111:5586-91.
139. Sun J, Ramos A, Chapman B, Johnnidis JB, Le L, Ho YJ, et al. Clonal dynamics of native haematopoiesis. Nature 2014;514:322-7
140. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 2002;99:15649-54.
141. Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011;17:320-9.
142. Caulin AF, Maley CC. Peto’s Paradox: evolution’s prescription for cancer prevention. Trends Ecol Evol 2011;26:175-82.
143. Keane M, Semeiks J, Webb AE, Li YI, Quesada V, Craig T, et al. Insights into the evolution of longevity from the bowhead whale genome. Cell Rep 2015;10:112-22.
144. Gorbunova V, Seluanov A, Zhang Z, Gladyshev VN, Vijg J. Comparative genetics of longevity and cancer: insights from long-lived rodents. Nat Rev Genet 2014;15:531-40.
145. DePinho RA. The age of cancer. Nature 2000;408:248-54
146. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 2010;10:353-61.
147. Doll R, Peto R. The causes of cancer. Oxford: Oxford University Press; 1981.
148. Greaves M. Darwinian medicine: a case for cancer. Nat Rev Cancer 2007;7:213-21.
149. Kirkwood TB, Austad SN. Why do we age? Nature 2000;408:233-8
150. Gurven M, Kaplan H. Longevity among hunter-gatherers: a cross cultural examination. Popul Dev Rev 2007;33:321-65.
151. Eaton SB, Pike MC, Short RV, Lee NC, Trussell J, Hatcher RA, et al. Women’s reproductive cancers in evolutionary context. Quart Rev Biol 1994;69:353-67.
152. Greaves M. Was skin cancer a selective force for black pigmentation in early hominin evolution? Proc Biol Sci B 2014;281:2013-2955
153. Jablonski NG, Chaplin G. Human skin pigmentation as an adaptation to UV radiation. Proc Natl Acad Sci U S A 2010;107(Suppl 2): 8962-8.
154. Weiss KM. Are the known chronic diseases related to the human lifespan and its evolution? Am J Hum Biol 1989;1:307-19
155. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
156. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, et al. Growth hormone receptor defi ciency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011;3:70ra13.
157. Goedert JJ, editor. Infectious causes of cancer. New Jersey: Humana Press; 2000.
158. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006;6:193-203.
159. Johnson PA, Giles JR. The hen as a model of ovarian cancer. Nat Rev Cancer 2013;13:432-6.
160. Leroi AM, Koufopanou V, Burt A. Cancer selection. Nat Rev Cancer 2003;3:226-31.
161. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer. N Engl J Med 2000;343:78-85.
162. Sur IK, Hallikas O, Vaharautio A, Yan J, Turunen M, Enge M, et al. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science 2012;338:1360-3
163. Crespi BJ, Summers K. Positive selection in the evolution of cancer. Biol Rev Camb Philos Soc 2006;81:407-24.
164. Greaves M. Cancer causation: the Darwinian downside of past success? Lancet Oncol 2002;3:244-51.
165. Voight BF, Kudaravalli S, Wen X, Pritchard JK. A map of recent positive selection in the human genome. PLoS Biol 2006;4:e72
166. Izagirre N, Garcia I, Junquera C, de la Rua C, Alonso S. A scan for signatures of positive selection in candidate loci for skin pigmentation in humans. Mol Biol Evol 2006;23:1697-706.
167. Zeron-Medina J, Wang X, Repapi E, Campbell MR, Su D, Castro-Giner F, et al. A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection. Cell 2013;155:410-22.
168. Goldberg DE, Siliciano RF, Jacobs WR Jr. Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell 2012;148:1271-83
169. Greaves M. An evolutionary foundation for cancer control. In: Stewart BW, Wild CP, editors. IARC World Cancer Report 2014. Lyon: International Agency for Research on Cancer (IARC); 2014. p. 337-45.
170. Tomasetti C, Vogelstein B. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015;347:78-81
171. Losos JB. Convergence, adaptation, and constraint. Evolution 2011; 65:1827-40.
172. Stern DL, Orgogozo V. Is genetic evolution predictable? Science 2009;323:746-51.
173. de Visser JA, Krug J. Empirical fitness landscapes and the predict-ability of evolution. Nat Rev Genet 2014;15:480-90.
174. Palmer AC, Kishony R. Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. Nat Rev Genet 2013;14:243-8.
175. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38:468-73.
176. Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 2013;119:3034-42.
177. Anderson ARA, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006;127:905-15.
178. Yuan Y, Failmezger H, Rueda OM, Ali HR, Graf S, Chin SF, et al. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med 2012;4:157ra43
179. Herrera M, Islam AB, Herrera A, Martin P, Garcia V, Silva J, et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res 2013;19:5914-26.
180. Win T, Miles KA, Janes SM, Ganeshan B, Shastry M, Endozo R, et al. Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. Clin Cancer Res 2013;19:3591-9.
181. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012;30:679-92
182. Zhao B, Pritchard JR, Lauffenburger DA, Hemann MT. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov 2014;4:166-74.
183. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011;145:30-8.
184. Basanta D, Anderson AR. Exploiting ecological principles to better understand cancer progression and treatment. Interface Focus 2013;3:20130020.
185. Korolev KS, Xavier JB, Gore J. Turning ecology and evolution against cancer. Nat Rev Cancer 2014;14:371-80.
186. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
187. Kostadinov RL, Kuhner MK, Li X, Sanchez CA, Galipeau PC, Paulson TG, et al. NSAIDs modulate clonal evolution in Barrett’s esophagus. PLoS Genet 2013;9:e1003553.
188. Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to ST1571 in vitro. Blood 2002;99:319-25.
189. Fischer A, Vazquez-Garcia I, Mustonen V. The value of monitoring to control evolving populations. Proc Natl Acad Sci U S A 2015;112:1007-12
190. Levy SF, Blundell JR, Venkataram S, Petrov DA, Fisher DS, Sherlock G. Quantitative evolutionary dynamics using high-resolution lineage tracking. Nature 2015;519:181-6.
191. Weinreich DM, Delaney NF, Depristo MA, Hartl DL. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 2006;312:111-4.
192. Fischer A, Vazquez-Garcia I, Illingworth CJ, Mustonen V. Highdefinition reconstruction of clonal composition in cancer. Cell Rep 2014;7:1740-52.
193. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-10.
194. Sottoriva A, Spiteri I, Piccirillo SGM, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma refl ects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 2013;110:4009-14.
195. Davies PC, Lineweaver CH. Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors. Phys Biol 2011;8:015001.
196. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011;473:384-8
197. Basanta D, Gatenby RA, Anderson AR. Exploiting evolution to treat drug resistance: combination therapy and the double bind. Mol Pharm 2012;9:914-21.
198. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res 2009;69:4894-903.
199. Chen G, Mulla WA, Kucharavy A, Tsai HJ, Rubinstein B, Conkright J, et al. Targeting the adaptability of heterogeneous aneuploids. Cell 2015;160:771-84.
200. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012;4:127ps10.
201. Wang J, Lu F, Ren Q, Sun H, Xu Z, Lan R, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res2 011;71:7238-49.